Perigon Wealth Management LLC Has $236,000 Holdings in Becton, Dickinson and Company $BDX

Key Points

• Perigon Wealth Management LLC reduced its holdings in Becton, Dickinson and Company by 53.0% during the second quarter, leaving it with shares valued at $236,000.
• Several hedge funds have also adjusted their positions, with Penn Davis McFarland Inc. increasing its holdings by 81.3%, now owning shares worth $2,542,000.
• Becton, Dickinson and Company reported a quarterly earnings per share (EPS) of $3.68, exceeding analyst estimates, with revenue growth of 10.4% year-over-year.

Perigon Wealth Management LLC lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 53.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,369 shares of the medical instruments supplier's stock after selling 1,542 shares during the period. Perigon Wealth Management LLC's holdings in Becton, Dickinson and Company were worth $236,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Jeppson Wealth Management LLC acquired a new position in Becton, Dickinson and Company in the second quarter valued at $216,000. Penn Davis Mcfarland Inc. lifted its holdings in Becton, Dickinson and Company by 81.3% in the second quarter. Penn Davis Mcfarland Inc. now owns 14,758 shares of the medical instruments supplier's stock valued at $2,542,000 after buying an additional 6,620 shares during the period. TD Private Client Wealth LLC lifted its holdings in Becton, Dickinson and Company by 39.0% in the second quarter. TD Private Client Wealth LLC now owns 7,244 shares of the medical instruments supplier's stock valued at $1,248,000 after buying an additional 2,034 shares during the period. Foster Victor Wealth Advisors LLC lifted its holdings in Becton, Dickinson and Company by 40.4% in the second quarter. Foster Victor Wealth Advisors LLC now owns 39,274 shares of the medical instruments supplier's stock valued at $6,893,000 after buying an additional 11,308 shares during the period. Finally, Northside Capital Management LLC acquired a new position in Becton, Dickinson and Company in the second quarter valued at $7,939,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company's stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock valued at $562,036 over the last ninety days. 0.36% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BDX shares. Piper Sandler restated a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Argus boosted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $205.40.

Becton, Dickinson and Company Trading Up 2.0%

Shares of BDX stock opened at $190.90 on Thursday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The company has a 50-day simple moving average of $188.71 and a two-hundred day simple moving average of $188.20. The company has a market capitalization of $54.72 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the prior year, the firm posted $3.50 EPS. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.